Lexeo registers Phase 2 crossover trial of LX2006 gene therapy for Friedreich ataxia cardiomyopathy

Lexeo Therapeutics has one new trial listing this week.

• Lexeo Therapeutics is recruiting for a Phase 2, multicenter, open-label, randomized, controlled study evaluating LX2006 gene therapy in participants with Friedreich ataxia cardiomyopathy, known as SUNRISE-FA 2¹. The study uses a crossover design and plans to enroll 26 participants¹. LX2006 is described as an adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)¹. In the adult cohort, participants will receive usual care for 26 weeks before receiving treatment with LX2006 in a single crossover¹, while the pediatric cohort will not be randomized, with all participants receiving LX2006 upon enrollment after safety has been assessed in the adult cohort¹. The primary outcome for the adult cohort is percent change from baseline in left ventricular mass index by cardiac MRI at Week 26¹.